'n Nuwe insulienpreparaat met 100 eenhede per milliliter (U-100) word nou in Suid-Afrika bemark. Hierdie sterkte skakel aan by die wêreldwye metriseringstendens en is reeds in sommige lande die enigste insuliensterkte wat toegelaat word.
A new p re p a ra tio n o f insulin co n taining 100 u n its p e r m illilitre (U -100) is b ein g in tro d u c e d in S outh A frica. Since it w as first used in 1922, insulin h as b e e n av ailable in at least eig h t d iffe re n t c o n c e n tra tio n s b u t, o v er th e y e a rs, only th e 40 U /m l an d 80 U /m l h av e b e e n in co m m on u sag e, th e 20 U /m l having a c ertain vogue in th e U n ite d K in g d om only.
T h e m u ltiplicity o f syringes avail able to d iab etics h as b e e n o n e of th e m ain facto rs c re a tin g con fu sio n a b o u t d o sag e. Som e o f o u r p a tie n ts are still using old B ritish S ta n d a rd syringes w ith 20 m ark s/m l an d have to calcu late u n it d o ses in te rm s of syringe divisions, m ultiplying by 2 o r 4 acco rd in g to th e p a rtic u la r in sulin stre n g th . T h e syringes m ost com m only u sed h ave b o th U -40 and U -80 m ark in g s in a stag g ered fashion o n th e b a rre l; th is d u a l scale is visually co m p lic a te d an d d istra c t ing. A c c id e n ta l u se o f th e w rong scale can resu lt in significant dosage e rro r. T h e re c e n t in tro d u c tio n of syringes w ith single scale m ark in g s and individual c o lo u r d istin ctio n , has c o n trib u te d so m e w h a t in sim plifying th e p ro b le m . H o w ev er, c o n sid erab le co n fusion still exists in th e m inds o f d iab e tic p a tie n ts, d o c to rs, n u rses an d p h a rm a cists. V a ri o us stu d ies (Jo slin , 1974) , have show n th a t fro m 10% up to 58% of p a tie n ts have a co m p letely e rro n eo u s id e a o f th e ir insulin dosage. C o m m o n e rro rs a re difficulty w ith d ose calc u latio n , use o f th e w rong scale o n dual-scale syringes, dis p en sin g o f th e w rong insulin co n c e n tra tio n by th e p h arm a cist and m ixing o f d iffe re n t insulin co n c e n tra tio n s in th e sam e syringe.
M o st d o c to rs tre a tin g d iabetic p a tie n ts a re aw are th a t e rro rs in d o sage a re very co m m o n an d m ay lead to loss o f m etab o lic c o n tro l, h y p o -g ly c a e m ia o r k e to a c id o s is w ith serious co n se q u e n ce s. It is o u r resp o n sib ility to p re v e n t this from h a p p e n in g , an d it will soon be p o ss ible fo r us to do so. T h e in tro d u c tio n o f a new stre n g th o f insulin at 100 U /m l to g e th e r w ith a new sta n d a rd syringe g ra d u a te d d irectly in u n its o f insulin will e lim in ate the p r e s e n t c o n f u s io n a n d d o s a g e e rro rs. U -100 is th e only insulin stre n g th available in th e U n ite d S ta te s, C a n a d a , A u stra lia , N ew Z e a la n d an d has recen tly b e en a p p ro v e d by all p ro fessio n al b o d ies in th e U n ite d K ingdom (B lo o m et al, 1981) . A lre a d y m ost d iab eto lo g ists in S o u th A frica have ex pressed th e ir e n th u siasm fo r th e p rin cip le of U -100 as th e sole insulin stre n g th .
U -100 is n o t a new universal in sulin b u t m erely a m o re co n c e n tra te d stre n g th o f th e presen tly availab le insulins. It ca n n o t be e m p hasised sufficiently th a t o n e (1) u nit o f insulin is exactly th e sam e reg ard less o f th e stre n g th . A unit is alw ays c o n stan t an d it m e asu res a specific a m o u n t o f activity and is th e sam e fo r every insulin. If a p erso n in jec ts 35 u n its o f U -40, U -80 o r U -100 insulin, th e do se d e livered is exactly 35 u n its provided the syringe m atches the insulin. T he differen ce is only in c o n c e n tra tio n .
C o n v e rtin g to th e use o f U -100 insulin is a logical ste p in k eep in g w ith w orld-w ide tre n d s to w ard ad o p tio n o f th e m e tric system . It will sim plify m a tte rs by red u cin g b o th th e v o lu m e o f insulin in je cte d an d th e ch ances fo r e rro rs. Plastic syringes fo r U -100 will be readily av ailab le; if re -u se d a few tim es, th ey a re very c h e a p a n d safe, (G re e n o u g h et al, 1979), a n d , b e cause o f th e ir negligible d e a d sp ace, th ey lead to less insulin w astag e and m o r e a c c u r a t e a n d c o n s i s t e n t dosage w h en insulins o f d ifferen t d u ra tio n o f activity a re m ixed. F o r ch ildren and p a tie n ts w ho req u ire sm all insulin d o ses, a U -100 syringe o f 0,5m l capacity acc o m o d a tin g 50 units will be available. T his is n arro w b o re d a n d w idely g au g ed , so th a t e v e n Vz o r 1 u n it can be m e a su re d readilv.
A t first g lance, it w ould seem th a t th e decision to in tro d u c e a new stre n g th w ith o u t w ith d raw in g the old o n es on th e m a rk e t will be a dis ad v an tag e and ad d to th e p re se n t confusion. It w as a rg u ed ho w ev er, th a t o u r c o u n try 's m ain c e n tre s and p o p u latio n b ein g so w idely scat te re d , a rb itra ry legislatio n to stop th e reg istra tio n o f U -40 an d U -80 insulins w ould have re su lte d in chaos. It is to be h o p e d th a t th e m edical p ro fessio n in S o u th A frica -d ia b e t ic c lin ic s , p h y s ic ia n s , p aed iatrician s an d g en eral p ra c ti tio n e rs -will c o -o p e ra te in e n s u r ing a sm o o th ch an g e o v e r to th e new insulin stre n g th . H o p efu lly , also , all insulin m a n u fa c tu rers an d im p o rt ers will follow suit in o fferin g a single insulin stre n g th , a n d will tak e th e o p p o rtu n ity , w hen th is chan g e is effected , to m ak e availab le only in sulins o f h ig h e r p u rity .
A p ro g ra m m e fo r in fo rm in g an d in structin g d o c to rs an d p a tie n ts is alread y u n d erw ay to e n su re th a t acu te p ro b lem s o f gross dosage changes d o n o t arise. N ew ly diag n o sed d iabetics sh o u ld b e sta rte d im m ed iately on th e new insulin stre n g th an d it is also w ise fo r all diab etics to co n v ert to th e new stren g th as soon as possible. T he ch an g eo v er is easy as th e sam e n u m b e r o f u n its are u sed. H o w ev er, as th e new insulin stre n g th is only m a rk e te d in th e highly pu rified m o n o c o m p o n e n t v ariety , it is w ise, in th e case o f p a tie n ts being changed from th e old im p u re insulins, to red u ce th e to ta l dose by a b o u t 2 0 % , th e re a fte r m aking a p p ro p ria te a d ju stm e n ts.
M a jo r ad vances in th e m a n ag e m e n t o f in su lin -req u irin g diabetics will ta k e place in th e n e a r fu tu re . It is to be h o p e d th a t th e large n u m b er o f insulin p re p a ra tio n s will b e re d u ced , th a t all insulins will b e avail able in highly p u rified form an d in U -100 stre n g th o n ly , to g e th e r w ith a new n o -d ead space syringe. W e believe th a t this u n ifo rm ity , c o n venience an d eco n o m y will u ltim a tely be in th e in te re st o f th e diab etic p atien ts and in crease th e safety o f th e ir tre a tm e n t.
